+86-27-65522453 sales@sun-shinechem.com

Everolimus(RAD001)

Catalog No.: 81301
Cas No.: 159351-69-6
Purity : 98% by HPLC 
81301 - Everolimus(RAD001) | CAS 159351-69-6

Catalog number : 81301

CAS number : 159351-69-6

Molecular Formula : C53H83NO14 

Molecular Weight : 958.22 

Iupac Chemical Name : (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18- dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta16,24,26,28-tetraene-2,3,10,14,20-pentaone 

Smile : O[C@]12C(C(N3CCCC[C@H]3C(O[C@@H](CC([C@@H](\C=C(\[C@H]([C@H](C([C@@H](C[C@@H](\C=C\C=C\C=C(\[C@H](C[C@H](CC[C@H]1C)O2)OC)/C)C)C)=O)OC)O)/C)C)=O)[C@@H](C[C@H]2C[C@H]([C@@H](CC2)OCCO)OC)C)=O)=O)=O

InChiKey : HKVAMNSJSFKALM-GKUWKFKPSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsEverolimus,RAD001 
Molecular FormulaC53H83NO14 
Molecular Weight958.22 
AppearanceWhite solid powder 
Purity98% by HPLC 
SolubilitySoluble in DMSO 
Storage3 years -20ºCpowder 6 months-80ºCin solvent 
Shipping ConditionShipped under ambient temperature 
SmileO[C@]12C(C(N3CCCC[C@H]3C(O[C@@H](CC([C@@H](\C=C(\[C@H]([C@H](C([C@@H](C[C@@H](\C=C\C=C\C=C(\[C@H](C[C@H](CC[C@H]1C)O2)OC)/C)C)C)=O)OC)O)/C)C)=O)[C@@H](C[C@H]2C[C@H]([C@@H](CC2)OCCO)OC)C)=O)=O)=O
InChiKeyHKVAMNSJSFKALM-GKUWKFKPSA-N
InChiInChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
Coming soon.

Everolimus (INN) (earlier code name RAD001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).

It is currently used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.

It is marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and Afinitor in oncology. Everolimus also available with Biocon with the brand name of Evertor.

 

159351-69-6 - Request Bulk Quote

×
159351-69-6 - Request Bulk Quote
Change